Thozalinone

Chemical compound
  • none
Legal statusLegal status
  • In general: ℞ (Prescription only)
Identifiers
  • (RS)-2-(Dimethylamino)-5-phenyl-1,3-oxazol-4(5H)-one
CAS Number
  • 655-05-0 ☒N
PubChem CID
  • 12602
ChemSpider
  • 12082 checkY
UNII
  • 68X5932947
KEGG
  • D06115 checkY
ChEMBL
  • ChEMBL2105457
Chemical and physical dataFormulaC11H12N2O2Molar mass204.229 g·mol−13D model (JSmol)
  • Interactive image
ChiralityRacemic mixture
  • O=C2\N=C(/OC2c1ccccc1)N(C)C
InChI
  • InChI=1S/C11H12N2O2/c1-13(2)11-12-10(14)9(15-11)8-6-4-3-5-7-8/h3-7,9H,1-2H3 checkY
  • Key:JJSHYECKYLDYAR-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Thozalinone (USAN) (brand name Stimsen; former developmental code name CL-39808) is a psychostimulant that has been used as an antidepressant in Europe.[1][2][3][4][5] It has also been trialed as an anorectic.[6] Thozalinone is described as a "dopaminergic stimulant",[7] and likely acts via inducing the release of dopamine and to a minimal extent norepinephrine; similar to analogue pemoline, it is reportedly devoid of abuse potential unlike other dopaminergic psychostimulants.[2][7][8]

Synthesis

Synthesis: [9][10]

Sodium hydride is used as a strong base to abstract the alcohol proton in ethyl mandelate [774-40-3] (1); addition of the oxyanion to dimethylcyanamide [1467-79-4] gives the intermediate (2). Intramolecular cyclization then occurs giving Thozalinone (3).

Notes

  • In treatment of Parkinsonism: W. D. Gray, C. E. Edward, U.S. patent 3,665,075 (1972 to Am. Cyanamid).
  • Pharmacological studies:[11]

See also

References

  1. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 435–. ISBN 978-1-4757-2085-3.
  2. ^ a b Greenblatt EN, Osterberg AC (July 1965). "Some pharmacologic properties of thozalinone, a new excitant". Toxicology and Applied Pharmacology. 7 (4): 566–78. doi:10.1016/0041-008X(65)90042-6. PMID 4378772.
  3. ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. Archived from the original on 2021-05-31. Retrieved 2021-05-31.
  4. ^ Merck index on CD-ROM: Windows. London: Chapman & Hall EPD. 1998. ISBN 0-412-82910-X.
  5. ^ Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB (December 1966). "A double-blind study of thozalinone (C1 39,808) in depressed outpatients". Current Therapeutic Research, Clinical and Experimental. 8 (12): 621–2. PMID 4962734.
  6. ^ Leite AC, Liepen LL, Costa VP (September 1971). "[Clinical trial of Stimsem Thozalinone in the treatment of obese patients]". Revista Brasileira de Medicina (in Portuguese). 28 (9): 475–8. PMID 5139648.
  7. ^ a b Yen-Koo HC, Balazs T (1980). "Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice". Drug and Chemical Toxicology. 3 (2): 237–47. doi:10.3109/01480548009108286. PMID 6112126.
  8. ^ Yen-Koo HC, Davis DA, Balazs T (1985). "Inhibition of dopaminergic agonist-induced gnawing behavior by neuroleptic drugs in mice". Drug and Chemical Toxicology. 8 (6): 495–502. doi:10.3109/01480548509041072. PMID 2868876.
  9. ^ Howell CF, Quinones NQ, Hardy Jr RA (May 1962). "2-Amino-2-oxazolin-4-ones. I. Synthesis". The Journal of Organic Chemistry. 27 (5): 1679–1685. doi:10.1021/jo01052a047.
  10. ^ Lindberg UH, Pedersen J (February 1968). "Compounds related to pemoline. 2-amino-5-aryl-4-oxo-2-oxazolines". Acta Pharmaceutica Suecica. 5 (1): 15–22. PMID 4386169.
  11. ^ Bernstein BM, Latimer CN (1968). "Behavioral facilitation: The interaction of imipramine and desipramine with amphetamine, alpha-pipradrol, methylphenidate, and thozalinone". Psychopharmacologia. 12 (4): 338–345. doi:10.1007/BF00401412. PMID 4385109. S2CID 31096140.
  • v
  • t
  • e
AdamantanesAdenosine antagonistsAlkylaminesAmpakinesArylcyclohexylaminesBenzazepinesCathinonesCholinergicsConvulsantsEugeroicsOxazolinesPhenethylamines
PhenylmorpholinesPiperazinesPiperidinesPyrrolidinesRacetamsTropanesTryptaminesOthers
  • v
  • t
  • e
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Miscellaneous
  • v
  • t
  • e
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonists
GLP-1, GIP, and / or
glucagon agonists
DACRAs
5-HT2C
receptor agonists
Absorption inhibitors
Uncouplers
Others
  • v
  • t
  • e
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e